Lesogaberan

N/A

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameLesogaberan
Drug Alias Name来索伽兰lesogaberanum氟膦丙胺AZD-3355ARH-061746
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-Aminobutyric Acid B Receptor agonists
TargetsGamma-Aminobutyric Acid B Receptor
Therapy Area/IndicationsHeartburnGastroesophageal RefluxGastrointestinal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSweden +[10
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsHeartburnGastroesophageal RefluxGastrointestinal Diseases

Other Information

ATC CodeN/A
Related LinksWikipedia